Toronto-based Molagri, a crop protection startup that went through Y Combinator's Summer 2026 batch, announced US$5.8 million in total Pre-Seed and Seed funding on October 14, 2026. The financing is equivalent to 8.2 million Canadian dollars and was led by Convective Capital for the Seed round, with participation from Y Combinator, Superorganism, Robinhood Ventures, Paul Graham, and other angels. Julian Capital led the earlier Pre-Seed round and was the company's earliest institutional backer.
A Modular Virus-Like Particle Platform
Molagri's platform is built on non-infectious, engineered virus-like particles, or VLPs, that recognize receptors found only in target pest insects. Once inside the pest, each VLP delivers genetic instructions that cause the pest's own cells to produce an insecticidal payload. Beneficial insects lack the receptor, so the approach is designed to leave pollinators and other non-target species unaffected.
Initial Crop Targets and Resistance Pressure
The design is modular, allowing Molagri to adjust targeting and payload components as pest populations evolve rather than starting from scratch for every new problem. The company's first products will focus on pests affecting tree nuts and tree fruits, where growers face an acute need for novel insecticides. According to Molagri, broad-spectrum chemicals are increasingly undermined by resistance and regulatory removals.
Founders With Structural Biology Expertise
Molagri was co-founded by CEO Zaky Hassan and CSO Min Jin, viral structural biologists and protein biochemists from the University of Toronto who previously studied human coronaviruses. Jin holds the world record for the highest-resolution coronavirus spike protein structure in the Protein Data Bank. Hassan said the company wants to design the next product before resistance becomes a widespread field problem.
A Flu Shot Analogy for Farmers
Hassan compared the intended approach to a flu shot, noting that farmers should not have to worry about resistance in the same way patients do not think about which flu strain is circulating. He added that the new funding will let Molagri build out its lab and hire scientists. "We want to be the team that designs the next product before resistance becomes a problem in the field," Hassan said.
Investor Confidence and Expansion Plans
Bill Clerico, Managing Partner at Convective Capital, described pesticide resistance as a slow-moving disaster for global food security and said current tools were not built for pests that adapt quickly. He said Hassan and Jin are bringing the precision of modern protein engineering to agriculture. Clerico added that the platform could give growers a durable, targeted alternative to broad-spectrum chemicals.
Lab Expansion and Hiring
Molagri will use the capital to grow its scientific team and accelerate research and development. The company recently expanded into a new Toronto lab with biomanufacturing and tissue culture space and filed a provisional patent on its targeted VLP delivery system. It is currently hiring scientists in insect biology, virology, and VLP production.
With the new financing, Molagri is positioning itself to address one of agriculture's most persistent challenges through engineered biology rather than conventional chemistry. The company's virus-like particle platform is still in an early stage, but its modular design and initial focus on tree nuts and tree fruits give it a clear path toward commercial relevance. As regulatory pressure and pest resistance continue to reshape crop protection, the Toronto startup's work may offer growers a more durable and environmentally targeted option.